HealthQuill Pharma
Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy failed to show “sufficient evidence” of benefit to the patients.
Drugs Health Pharma

J & J stops rheumatoid arthritis trial due to lack of ‘sufficient evidence’

Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in females above 12 years and older, weighing at least 40 kilograms.
Drugs Health Pharma

GSK drug gets Britain’s nod to treat UTI patients 12 years and above

Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in.

Read More
Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.
Drugs Health Pharma

Biogen’s drug to treat postnatal depression gets UK regulator’s nod

Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.

Read More
Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in people born in 1990 than in 1995, a study reveals.
Drugs Pharma Research

Immunotherapy drug shows promising results against metastatic cancers

HQ Team August 16, 2025: Phase I clinical trial of the CD40 agonist antibody drug 2141-V11, developed by Rockefeller University’s Jeffrey V. Ravetch.

Read More
About 67 million people globally living with chronic fatigue syndrome have different genes compared to their healthy counterparts, initial findings from the world's largest research study on the illness reveal.
Health Pharma Research

UK researchers unravel 8 gene variants in chronic fatigue syndrome 

About 67 million people globally living with chronic fatigue syndrome have different genes compared to their healthy counterparts, initial findings from the world's.

Read More
Jazz Pharmaceuticals Plc’s treatment for a rare and aggressive brain tumour that affects children and adults got approval from the US regulator.
Drugs Health Pharma

Jazz Pharma’s oral drug for a type of brain tumour gets US approval 

Jazz Pharmaceuticals Plc’s treatment for a rare and aggressive brain tumour that affects children and adults got approval from the US regulator.

Read More
The Gates Foundation will support more than 40 innovations in five chronically underfunded areas in women’s health by spending $2.5 billion over the next five years.
Drugs Health Pharma

Gates Foundation to spend $2.5 billion on women’s health innovations

The Gates Foundation will support more than 40 innovations in five chronically underfunded areas in women’s health by spending $2.5 billion over the.

Read More
The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious kidney diseases.
Drugs Health Pharma

FDA approves Apellis’ therapy to treat two serious, rare kidney diseases

HQ Team July 30, 2025: The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious.

Read More
The US Food and Drug Administration cleared PTC Therapeutics’ sepiapterin for treating children and adults with a rare genetic condition where the body cannot break down a part of protein called phenylalanine, which comes from foods like meat, eggs, and milk.
Drugs Health Pharma

US regulator clears PTC’s medicine to treat a rare genetic metabolic disease 

HQ Team July 29, 2025: The US Food and Drug Administration cleared PTC Therapeutics’ sepiapterin for treating children and adults with a rare.

Read More
Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the Chinese company’s 12 potential medicines.
Drugs Health Pharma

GSK inks $500m deal with Jiangsu Hengrui for 12 potential medicines

HQ Team July 28, 2025: Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the.

Read More